GREM1 in HER2+ breast cancer: worse prognosis, larger tumours and more bone metastasis

      Breast cancer is the leading cause of female cancer deaths. Bone is the commonest site of breast cancer metastasis (40%) will be in the bone. Bone Morphogenetic Protein (BMP) antagonists have been shown to stimulate glycolysis as well as epithelial mesenchymal transition (EMT), which increases the motility of malignant cells and contributes to the development of metastases. The role of GREM1 in HER2+ breast cancer progression remains an under-researched yet promising area of study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect